MATRiC - Applied Medical Technology Research Center

Available Technology Banner

MATRiC - Applied Medical Technology Research Center

MATRiC - Applied Medical Technology Research Center


Director and Principal investigator: Arbel Artzy-Schnirman, PhD

The Applied Medical Technology Research Center (MATRiC) operates as a ‘focal knowledge hub’ in the field of regenerative medicine, from the cellular to the tissue level, with a focus on developing clinically relevant structured human tissues for transplantation, drug screening, and precision medicine.
The Center's professional team collaborates with researchers from Rambam, academia and leading industries to answer clinically unmet needs across the hospital's departments. Leveraging advanced technologies in the fields of stem cells, tissue engineering, 3D bioprinting, and organ-on-chip devices, the Center focuses on the following areas:    

Cellular level

Rambam researchers have been among the first in the world to create human pluripotent stem cells (embryonic and induced pluripotent stem cells) and develop differentiation protocols for a variety of cell types. In collaboration with Rambam's Biobank, the Center uses the following cell sources for tissue formation:
  •  iPSCs from patients with hereditary diseases 
  • iPSCs with a heterogeneous genetic background 
  • Adult stem cells 
  • Cancer cells 
  • Primary cells from biopsies

3D bioprinting

 3D printing drives significant innovations in many areas, such as engineering, manufacturing, and medicine. Recent advances have enabled 3D printing of biocompatible materials, cells, and supporting components for use as complex 3D functional living tissues. 3D bioprinting is being applied to address the need for tissues suitable for transplantation, such as multi-layered skin, bone, vascular grafts, heart tissue, and cartilaginous structures. Other applications include developing bioprinted tissue models for research, drug discovery, and toxicology.


Organs-on-chips are engineered physiological organ biomimetic systems. They simulate the organ's microenvironment in terms of tissue interfaces and mechanical stimulation, thus reflecting human tissue's structural and functional characteristics. Organ-on-chip models can help predict the response to various stimuli, including drug responses, environmental effects and molecular techniques such as CRISPR genetic editing and mRNA/siRNA-based treatments. A particularly intriguing aspect of organs-on-chips, which is of particular interest to researchers at MATRiC, is that they are a patient-specific tool and can be used for precision treatments.

The Center offers services in the fields mentioned above, from iPSC manufacturing to establishing an organ-on-chip platform. Its researchers support all the research stages, from designing experiments to operating instruments and data analysis and interpretation.

At MATRiC, we translate academic research into medical applications. We value all input and encourage inquiries for collaborations.

Please contact us for more information.
Arbel Artzy-Schnirman, Ph.D
Director, Applied Medical Technology Research Center
Tel: +972-4-7772467/  Email: [email protected]

MATRiC's Team>

Arbel Artzy-Schnirman, Ph.D

Director, Applied Medical Technology Research Center

Dr. Arbel Artzy-Schnirman completed her Ph.D. in Bionanotechnology at the Technion–Israel Institute of Technology in 2011. During her doctoral studies, she was the first to demonstrate a generic electrical-to-biological transducer comprising a two-state electronic antigen and a CAR-T cell engineered to bind the antigen exclusively in its “on” state.  Her work was inspired by biology where pathways are directed by molecular recognition.

Dr. Arbel Artzi-Schnirman

From 2011 to 2016, Dr. Artzy-Schnirman pursued postdoctoral research at Imperial College London in Prof. Molly Stevens' group in the Institute of Biomedical Engineering’s Department of Materials. Motivated by the need for antigen-specific immunotherapy approaches for autoimmune and inflammatory diseases, she led the development of a novel artificial antigen-presenting “cell” for detection and desensitization of auto-reactive T cells associated with type 1 diabetes. Using this platform, the team was able to detect rare populations of auto-reactive cells that could not be detected otherwise. 

In 2016, Dr. Artzy-Schnirman returned to Israel and to the Technion, joining the Biofluids lab in the Biomedical Engineering Department as a senior researcher and leading the development of preclinical in vitro platforms. Specifically, she spearheaded the development of a 3D lung organ-on-chip as a tumor model system recapitulating the microenvironment from human lung and metastatic breast cancer.

Her work has been published in leading peer-reviewed journals (
She has received numerous academic and professional awards, including the EMBO Research Fellow (co-funded by the European FP7), Weizmann Institute of Science National Postdoctoral Award Program, Clore Scholars Programme, Scholarship for Excellence in Research from the Israel Council for Higher Education, and a Scholarship for Excellence in Converging Technologies, among others.

In 2021, Dr. Artzy-Schnirman joined Rambam Health Care Campus and established the Applied Medical Technology Research Center (MATRiC). She is passionate about translating research into clinical applications by harnessing biomimetics and bioengineering for practical use, closing the loop of bench to bedside and back to the bench to refine novel therapeutic approaches through learning from patients. 

Dr. Arbel Artzy-Schnirman, originally from Kibbutz Amiad in Israel’s Upper Galilee region, is married to Guy and the mother of Itamar, Uri, and Ayala.